Wednesday, March 6, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery and productive longevity at AI Innovation in Pharma - Asia Pharma R&D Leaders Summit 2019 in Shanghai, April 16-17.
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective. The presentation will cover the recent progress in the end-to-end pipeline development at Insilico Medicine and recent advances in the generative adversarial networks (GANs) and reinforcement learning (RL) for generation of novel chemistry, identification of novel biological targets and real world evidence collection and analysis.
"We are happy to present our latest research at the Asia Pharma R&D Leaders Summit 2019, which gathers the leading longevity leaders. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
"AAIH looks forward to being part of the Asia Pharma R&D Leaders Summit and is excited that Dr. Zhavoronkov, whose company is one of the founding members of our organization, will be a principal presenter on AI innovation at this global gathering of pharma industry executives and scientific leaders," said AAIH President Annastasiah Mudiwa Mhaka, PhD., president of the Alliance for Artificial Intelligence in Healthcare (AAIH). Mhaka will join Zhavoronkov as a speaker in the AI Innovation in Pharma session to talk about trends and issues in the application of AI to healthcare and introduce AAIH's global advocacy efforts on behalf of this fast growing segment of the healthcare industry.
The Asia Pharma R&D Leaders Summit 2019 will bring in fresh perspectives and scientific advancement on emerging therapeutic areas in oncology, immuno-oncology, cell therapy, neurodegenerative diseases diabetes which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, targeting discovery, drugging the undruggable, promoting China innovation, medicinal chemistry outsourcing, AI innovation in pharma. APRDL 2019 is an opportunity to brainstorm with over 70 speakers and over 350 Global pharma R&D professionals. The event in held in Shanghai on April 16-17, 2019.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
For further information, images or interviews, please contact:
Contact: Polina Firsanova
Official website of the conference:
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/